Lilly restructuring (correction)
Executive Summary
Lilly Exec VP-Science & Technology Steve Paul reports to CEO Sidney Taurel. In a story on Lilly's restructuring, "The Pink Sheet" incorrectly stated that Paul reports to President & Chief Operating Officer John Lechleiter (1"The Pink Sheet" Sept. 26, 2005, p. 19)...
You may also be interested in...
Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel
Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.